Our Work

AWAKN Lifesciences

Making psychedelics mainstream

From start-up to IPO in 10 months, our work guided this innovative biotech as it launched psychedelic-assisted therapies as mainstream psychiatric treatment for the first time.

More Advice

Reshaping the narrative, using data, working with the influencers, challenging the status-quo – we overcame the prejudice for a novel group of therapies previously stigmatised as lifestyle drugs – ketamine, MDMA and psilocybin. Highlighting the rigorous research and significant clinical experience versus a category where outcomes are generally poor, and innovation rare; we launched a targeted media programme to change opinion.

More Conversations

From front pages of the Times, Guardian, Telegraph and features on BBC News, CH4 and ITV, to regular editorial in the global consumer, biotech and psychiatric media; attitudes have changed, and a new category in mental health treatment has been born.

205

Pieces of Coverage

3.3B

Online Readership

13

National Stories

11M

Offline Reach

Share this:

Ready for some fresh ideas?

Get In Touch